Get the Stockscreener App
183.06
0.64%
-1.015
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $183.06, with a volume of 115.74K.
It is down -0.64% in the last 24 hours and down -11.48% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$184.07
Open:
$182.63
24h Volume:
115.74K
Relative Volume:
0.02
Market Cap:
$284.02B
Revenue:
$58.80B
Net Income/Loss:
$10.24B
P/E Ratio:
55.83
EPS:
3.2788
Net Cash Flow:
$8.98B
1W Performance:
-4.39%
1M Performance:
-11.48%
6M Performance:
+142.70%
1Y Performance:
+146.86%
1-Day Range:
$182.39
$183.65
1-Week Range:
$182.39
$190.73
52-Week Range:
$61.24
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
183.14 | 285.46B | 58.80B | 10.24B | 8.98B | 3.2788 |
LLY
Lilly Eli Co
|
907.57 | 813.11B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
233.91 | 567.04B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
202.72 | 362.35B | 61.16B | 4.19B | 17.82B | 2.3614 |
MRK
Merck Co Inc
|
115.70 | 286.01B | 64.93B | 18.26B | 12.36B | 7.2751 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca reportedly hit by serious cyberattack - pharmaphorum
Astrazeneca plc Announces In-Licensing of Worldwide Rights from Astrazeneca to A Phase 3?Ready Novel Chemical Entity - marketscreener.com
AstraZeneca Data Breach: What You Need to Know - SOCRadar® Cyber Intelligence Inc.
Westview Management dba Westview Investment Advisors Invests $3.60 Million in Astrazeneca Plc $AZN - MarketBeat
Gradient Investments LLC Has $16.96 Million Holdings in Astrazeneca Plc $AZN - MarketBeat
LAPSUS$ Hackers Claim Breach of AstraZeneca’s Internal Systems - cyberpress.org
AstraZeneca Data BreachLAPSUS$ Group Allegedly Claims Access to Internal Data - CyberSecurityNews
AstraZeneca PLC stock faces March pressure amid 100% YTD surge on NYSE - AD HOC NEWS
Signet Financial Management LLC Invests $2.57 Million in Astrazeneca Plc $AZN - MarketBeat
Morgan Stanley sees double-digit EPS growth for AstraZeneca PLC (AZN) - MSN
AstraZeneca plc stock faces pressure amid monthly declines but shows YTD strength in volatile pharma - AD HOC NEWS
Patterns Watch: Whats the outlook for AstraZeneca PLC Depositary Receipts sectorRecession Risk & Daily Entry Point Trade Alerts - baoquankhu1.vn
AstraZeneca PLC (AZN) gains after successful Saphnelo trial - MSN
Hilltop National Bank Purchases 7,586 Shares of Astrazeneca Plc $AZN - MarketBeat
QP Wealth Management LLC Buys New Position in Astrazeneca Plc $AZN - MarketBeat
Astrazeneca (AZN) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Hacker Group LAPSUS$ Claims Alleged AstraZeneca Data Breach - Hackread
Form 6K AstraZeneca PLC ADR For: 20 March By Investing.com - Investing.com South Africa
AstraZeneca’s Pan-HER2 China Study Builds a Quiet Long-Term Edge in Oncology - TipRanks
AstraZeneca, Sanofi expand R&D footprint in China (AZN:NYSE) - Seeking Alpha
AstraZeneca admits 45,750 new shares to London Stock Exchange main market - Investing.com
AstraZeneca (AZN) admits 45,750 new employee scheme shares to LSE - Stock Titan
Park National Corp OH Has $12.82 Million Stock Position in Astrazeneca Plc $AZN - MarketBeat
Miller Global Investments LLC Buys Shares of 7,716 Astrazeneca Plc $AZN - MarketBeat
2 Healthcare Stocks to Buy Before They Get Bought Out - The Motley Fool
Astrazeneca (NYSE:AZN) Rating Increased to Buy at Wall Street Zen - MarketBeat
AstraZeneca PLC stock faces pressure on NYSE amid insider filings and China expansion news - AD HOC NEWS
Moody's Changes Outlook on AstraZeneca to Positive on Organic Track Record - marketscreener.com
AstraZeneca (AZN) officer Mani Sharma details share and award holdings - Stock Titan
AstraZeneca Expands Real-World Push With New China Kidney Registry - TipRanks
AstraZeneca’s REVIVE Trial Targets Relapse After Osimertinib, Extending the Lung Cancer Playbook - TipRanks
AstraZeneca to boost cell therapy capabilities with new China investment - BioPharma Dive
Wilmington Savings Fund Society FSB Cuts Stock Position in Astrazeneca Plc $AZN - MarketBeat
Hudson Bay Capital Management LP Acquires 128,256 Shares of Astrazeneca Plc $AZN - MarketBeat
AstraZeneca to build cell therapy base, innovation centre in Shanghai - marketscreener.com
AstraZeneca Makes Soliris Available In Malaysia For Rare Disease Treatment - bernama
Cowen Maintains AZN AstraZeneca PLC at Buy on March 18, 2026 - Meyka
AstraZeneca: The $6 Billion Imfinzi Story Is Expanding Beyond Lung Cancer - Smartkarma
Why AstraZeneca Stock Was a Winner Today - MSN
AstraZeneca (AZN) Price Target Backed by Goldman After Baxdrostat Phase 3 Data - MSN
Challenges for AstraZeneca (AZN) Amid Drug Pricing Claims - GuruFocus
AZN Stock Quote Price and Forecast - CNN
Why AstraZeneca PLC (AZN) is one of the best immunotherapy stocks to buy according to hedge funds - MSN
Astrazeneca Plc $AZN Shares Sold by CIBC Private Wealth Group LLC - MarketBeat
AstraZeneca PLC (LON:AZN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
AstraZeneca Advances Primary Care Lung Diagnosis Study With Global Reach - TipRanks
AstraZeneca's Imfinzi Secures Approval for Gastric Cancer in the EU - Yahoo Finance
Imfinzi EU Approval Expands AstraZeneca Gastric Cancer Reach For Investors - Yahoo Finance
AstraZeneca strikes up to $18.5B obesity drug deal with China’s CSPC Pharmaceutical - MSN
Sentiment Recap: Why is AstraZeneca PLC Depositary Receipt stock going up2026 Market Trends & Fast Gain Swing Alerts - baoquankhu1.vn
AstraZeneca (AZN) Faces Potential Impact from Recent Federal Rul - GuruFocus
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):